Oppenheimer bullish on Abbott (ABT) due to Volt system and diabetes innovation

From Yahoo Finance: 2025-06-25 15:08:00

Abbott Laboratories (NYSE: ABT) is a top stock for an early retirement portfolio, with Oppenheimer reaffirming a $140 price target and Outperform rating. The company’s Volt system and future glucose-ketone monitoring technology are driving confidence in its performance.

Oppenheimer sees strong upside for Abbott (ABT) thanks to the Volt system and diabetes innovation. The approval of Volt PMA and the integration of Abbott’s dual sensor system with Tandem Diabetes Care’s insulin pump are expected to boost the company’s performance in the second half of 2025.

Abbott Laboratories (NYSE: ABT) is a global healthcare company known for manufacturing branded generic medications, medical devices, diagnostics, and nutritional products. While ABT shows investment potential, some AI stocks may offer greater upside with less downside risk.

For investors seeking undervalued AI stocks, a free report on the best short-term AI stock is available. Despite the potential of ABT, other opportunities may offer significant benefits in the current market landscape. Explore the 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds for more insights.

Read more: Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation